The Nevada attorney general’s office has filed a “friend of the court” brief on behalf of the state of Maryland in its continuing battle against prediction markets that are taking sports bets the ...
BioMarin: $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio; Shares Surge 18%
BioMarin plans to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, representing a 33% premium to Amicus' last close for a total equity value of $4.8 billion. BioMarin's ...
・The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. ・Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin ...
BioMarin BMRN-1.57%decrease; red down pointing triangle Pharmaceutical has struck a deal to buy fellow biotech Amicus Therapeutics FOLD-0.14%decrease; red down pointing triangle for about $4.8 billion ...
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Friday it would acquire Amicus Therapeutics (FOLD.O), opens new tab for about $4.8 billion, in the drugmaker's second deal ...
Rare disease drug developer BioMarin Pharmaceutical is buying its way to revenue growth with a $4.8 billion deal for Amicus Therapeutics, a company whose two commercialized products each offer ...
BioMarin Pharmaceutical (BMRN) has agreed to acquire rare disease drug developer Amicus Therapeutics (FOLD) in an all-cash transaction worth nearly $4.8B, the companies announced on Friday. The deal, ...
Sixteen months after luring former Roche dealmaker James Sabry, M.D., Ph.D., out of retirement and signaling a shift in its business development approach, BioMarin has announced the largest ...
The all-cash acquisition price translates to $14.50 per share, valuing the offer at a 33% premium to Amicus's last close, a 46% premium to its 30-day average price, and a 58% premium to its 60-day ...
SAN RAFAEL, Calif., and PRINCETON, N.J., Dec. 19, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback